Lantern Pharma Inc. — Form 8-K
Filed November 18, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Lantern Pharma closed a $4.0M registered direct offering (1,469,725 shares at $1.09/share plus warrants) on September 30, 2026, bringing cash to $7.6M as of that date. CEO Panna Sharma resigned November 15, 2026; CFO David Margrave appointed Interim CEO. Company accrued $2.0M for a proposed settlement with a former consultant alleging discrimination and harassment (terms: $1M within 30 days, $1M upon raising $10M or in 2 years). Company disclosed substantial doubt about going concern for next 12 months.
Why this rating
Capital raise extends runway but modest relative to $33.9M market cap; CEO departure mid-turnaround is material governance risk; $2M settlement is 5.9% of market cap and 26% of cash. Going-concern warning is serious for clinical-stage biotech.
Tradability signal
NO TRADE
No trade: price $0.36 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · unknown $0.36 | +10 min · unknown $0.36 ▲ 0.83% | +30 min · unknown $0.38 ▲ 4.72% | +1 hr · unknown $0.36 ▲ 0.00% | +4 hrs · unknown $0.34 ▼ 6.39% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.